These novel medications , Semaglutide , represent a remarkable advancement in treating type 2 diabetes and conceivably related ailments . They are classified as GLP-1 pathway stimulators, signifying these substances to replicate the body's GLP-1 substance , stimulating insulin secretion and suppressing appetite . Despite Retatrutide each works some